and get StockInvest.us Premium Subscription for FREE
Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Blueprint Medicines Corporation Stock Price (Quote) NASDAQ:BPMC
$54.41 ( 8.97% ) Tuesday, 5th Jul 2022
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $43.46 | $65.00 | Tuesday, 5th Jul 2022 BPMC stock ended at $54.41. This is 8.97% more than the trading day before Friday, 1st Jul 2022. During the day the stock fluctuated 11.88% from a day low at $48.64 to a day high of $54.42. |
| 90 days | $43.46 | $71.58 | |
| 52 weeks | $43.46 | $117.86 |
Historical Blueprint Medicines Corporation prices
| Date | Open | High | Low | Close | Volume |
| 2022-07-05 | $50.00 | $54.42 | $48.64 | $54.41 | 1 061 272 |
| 2022-07-01 | $50.57 | $50.80 | $48.51 | $49.93 | 1 012 342 |
| 2022-06-30 | $52.24 | $52.34 | $49.33 | $50.51 | 1 070 051 |
| 2022-06-29 | $53.20 | $53.20 | $50.91 | $52.21 | 682 174 |
| 2022-06-28 | $57.50 | $57.50 | $53.17 | $53.46 | 760 748 |
| 2022-06-27 | $57.48 | $58.67 | $55.98 | $57.38 | 747 579 |
| 2022-06-24 | $57.38 | $60.20 | $56.72 | $60.15 | 954 675 |
| 2022-06-23 | $53.53 | $56.40 | $53.10 | $56.38 | 623 384 |
| 2022-06-22 | $49.94 | $53.74 | $49.75 | $53.03 | 510 916 |
| 2022-06-21 | $49.16 | $51.78 | $49.16 | $50.64 | 544 389 |
| 2022-06-17 | $47.23 | $50.82 | $46.93 | $48.63 | 1 321 929 |
| 2022-06-16 | $46.53 | $47.12 | $44.96 | $46.78 | 1 034 081 |
| 2022-06-15 | $46.08 | $48.91 | $46.08 | $47.97 | 912 048 |
| 2022-06-14 | $44.59 | $45.72 | $43.46 | $45.60 | 1 073 306 |
| 2022-06-13 | $45.78 | $46.26 | $43.86 | $45.23 | 2 905 100 |
| 2022-06-10 | $54.10 | $54.50 | $47.71 | $48.07 | 3 795 531 |
| 2022-06-09 | $63.12 | $63.19 | $56.56 | $58.77 | 1 885 663 |
| 2022-06-08 | $62.75 | $65.00 | $62.26 | $64.50 | 568 085 |
| 2022-06-07 | $57.46 | $62.62 | $57.34 | $62.62 | 809 727 |
| 2022-06-06 | $60.17 | $60.36 | $57.58 | $57.94 | 947 860 |
| 2022-06-03 | $58.36 | $60.89 | $56.95 | $59.35 | 1 009 866 |
| 2022-06-02 | $55.70 | $57.32 | $55.10 | $56.75 | 230 381 |
| 2022-06-01 | $56.41 | $57.98 | $54.87 | $56.04 | 759 705 |
| 2022-05-31 | $55.88 | $56.72 | $54.01 | $55.00 | 599 342 |
| 2022-05-27 | $55.57 | $56.72 | $54.59 | $56.29 | 478 295 |
| 2022-05-26 | $56.37 | $56.75 | $54.45 | $55.36 | 562 577 |
| 2022-05-25 | $55.00 | $56.07 | $53.97 | $55.94 | 388 766 |
| 2022-05-24 | $56.31 | $56.31 | $53.98 | $55.33 | 323 860 |
| 2022-05-23 | $57.67 | $57.67 | $56.16 | $56.91 | 378 052 |
| 2022-05-20 | $58.04 | $58.83 | $56.50 | $57.37 | 431 821 |
| 2022-05-19 | $55.13 | $57.04 | $54.32 | $56.96 | 620 869 |
| 2022-05-18 | $56.49 | $58.10 | $55.00 | $55.50 | 374 902 |
| 2022-05-17 | $57.44 | $58.53 | $56.85 | $58.47 | 397 046 |
| 2022-05-16 | $54.57 | $56.64 | $53.45 | $56.21 | 390 668 |
| 2022-05-13 | $55.55 | $56.06 | $54.52 | $54.95 | 944 105 |
| 2022-05-12 | $51.52 | $55.17 | $50.96 | $54.03 | 650 365 |
| 2022-05-11 | $53.54 | $55.41 | $51.79 | $52.16 | 727 181 |
| 2022-05-10 | $54.14 | $56.32 | $51.33 | $53.72 | 994 567 |
| 2022-05-09 | $55.67 | $56.42 | $51.46 | $51.85 | 906 212 |
| 2022-05-06 | $59.39 | $59.75 | $56.02 | $56.64 | 1 021 359 |
| 2022-05-05 | $63.26 | $63.26 | $59.35 | $60.33 | 830 912 |
| 2022-05-04 | $61.62 | $64.01 | $60.37 | $63.26 | 872 836 |
| 2022-05-03 | $60.94 | $64.55 | $59.87 | $62.82 | 710 772 |
| 2022-05-02 | $58.30 | $59.74 | $57.04 | $59.72 | 657 551 |
| 2022-04-29 | $59.76 | $61.76 | $58.10 | $58.35 | 471 203 |
| 2022-04-28 | $60.51 | $61.02 | $57.82 | $60.23 | 442 541 |
| 2022-04-27 | $60.93 | $61.70 | $59.30 | $59.73 | 461 216 |
| 2022-04-26 | $64.75 | $65.17 | $61.35 | $61.38 | 380 656 |
| 2022-04-25 | $62.80 | $65.33 | $62.68 | $65.10 | 502 004 |
| 2022-04-22 | $64.41 | $65.08 | $63.02 | $63.52 | 384 800 |
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patie... ![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
